^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INCAGN1949

    i
    Other names: INCAGN1949, INCAGN01949, INCAGN 01949, INCAGN 1949
    Associations

    News

    Trials
    Company:
    Agenus, Incyte
    Drug class:
    OX40 agonist
    Related drugs:
    Associations

    News

    Trials
    almost2years
    CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (clinicaltrials.gov)
    P1/2, N=2, Terminated, University of Southern California | N=42 --> 2 | Trial completion date: Apr 2024 --> Dec 2022 | Recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Dec 2022; Study drug no longer available
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    vidutolimod (CMP-001) • INCAGN1949
    3years
    CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (clinicaltrials.gov)
    P1/2, N=42, Recruiting, University of Southern California | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    vidutolimod (CMP-001) • INCAGN1949
    over3years
    CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, University of Southern California | Trial completion date: Jul 2023 --> Jul 2024 | Initiation date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2022 --> Jul 2023
    Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    vidutolimod (CMP-001) • INCAGN1949
    over4years
    CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, University of Southern California | Trial completion date: Dec 2022 --> Jul 2023
    Clinical • Trial completion date • Combination therapy
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    vidutolimod (CMP-001) • INCAGN1949
    over4years
    CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, University of Southern California
    Clinical • New P1/2 trial • Combination therapy
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    vidutolimod (CMP-001) • INCAGN1949